Biotechnological Insights into LncRNA-STAT3 Interactions: A Novel Diagnostic Biomarker for Myocardial Hypertrophy.

BACKGROUND

Advances in molecular biology have highlighted the significant role of long non-coding RNAs (lncRNAs) in cardiovascular diseases, including myocardial hypertrophy (MH). This study integrates bioinformatics analysis with molecular validation to investigate the regulatory mechanism of lncRNA ENST00000500113.1 on STAT3 expression, aiming to identify novel biomarkers for MH diagnosis.

OBJECTIVES

We aimed to explore differential expression patterns of lncRNAs and mRNAs in myocardial hypertrophy using biotechnological approaches and establish their potential as diagnostic and therapeutic targets. The study aims to provide actionable insights that can facilitate the development of biotechnological tools for early diagnosis and intervention in myocardial hypertrophy.

MATERIALS AND METHODS

Myocardial tissues from organ donor patients were classified into control and hypertrophy groups. RNA sequencing was performed to identify differentially expressed genes. Advanced bioinformatics techniques were applied for functional enrichment analysis and co-expression network construction. Validation was conducted using qRT-PCR and immunohistochemistry.

RESULTS

Bioinformatics analyses revealed that MH-associated mRNAs were enriched in immune system processes and the JAK/STAT signaling pathway. Downregulation of lncRNA ENST00000500113.1 in MH tissues was correlated with upregulated STAT3 expression. Molecular validation confirmed a significant association between ENST00000500113.1 and STAT3, suggesting a regulatory mechanism contributing to MH progression.

CONCLUSIONS

This study demonstrated the biotechnological potential of integrating bioinformatics and molecular validation to identify lncRNA ENST00000500113.1 as a novel diagnostic biomarker for MH. These findings offer actionable insights into MH pathophysiology and facilitate the development of targeted interventions.